VIDEO: Study explores real-world treatment patterns of faricimab for wet AMD
Click Here to Manage Email Alerts
In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Sophie J. Bakri, MD, discusses outcomes from the FARETINA-AMD study of faricimab as a treatment for age-related macular degeneration.
Data from the IRIS Registry was used to examine faricimab treatment patterns. Patients with a diagnosis of AMD, one or more faricimab injections from February 2022 to June of 2023, 6 months or more of follow-up and two or more best documented visual acuity measures on or after the first injection were included in the analysis. The researchers examined the interval extension of faricimab, defined as 6 weeks or greater between injections, Bakri explained.
“More than 50% of the eyes with wet AMD were able to achieve an extended faricimab interval of 6 weeks or greater within two initial injections of faricimab,” Bakri said.
Collapse
Bakri SJ. Real-world outcomes and treatment patterns with faricimab in AMD. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts